arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AbCellera Biologics Inc.

ABCL
$11.12 ▼ -1.16 (-9.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

AbCellera Biologics Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.4B
Dividend Yield —
Revenue Growth -76.3% ↘
Op. Margin None
ROIC -6.6% ↘
FCF / Share $0.08 ↗
Trailing P/E —
Price / Book 3.8x
FCF Yield 0.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.05M
↓ -76.3% —
Net Income Profit after all expenses
$-43.16M
↑ +5.4% —
Operating Margin Operating profit as % of sales
-63.7%
↑ +78.0% 0th
FCF / Share Free cash flow per share
$0.08
↑ +163.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
30
Cash Quality →
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 28 quarters